ArticleDermatology and therapy2026

Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).

Gil Yosipovitch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.